Natural Phenomenon or Process – Page 4

Breaking the Silence: Endo’s “I Got Somebody” Campaign Encourages Men to Seek Help for Peyronie’s Disease

3 months ago talkbio0Tagged Awareness, campaign, Endometriosis, Hospital specialist, men 's health, nonsurgical treatment options, Peyronie 's disease, Social stigmata, Urology

Peyronie’s disease, men’s health, Endo, “I Got Somebody” campaign, urology specialists, nonsurgical treatment options, disease awareness, stigma reduction.

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

4 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

Scribe Therapeutics Prepares for Clinical Trials by Streamlining Workforce Amid Advances in Cardiometabolic Genetic Medicines

4 months ago talkbio0Tagged cardiometabolic disease, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, epigenetic modification, Gene Modification

Scribe Therapeutics, cardiometabolic disease, CRISPR, gene editing, epigenetic modification, clinical trials, workforce reduction

LB Pharma’s Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial

4 months ago talkbio0Tagged benzamide antipsychotic, first-in-class, LB-102, PANSS, Phase 2 Clinical Trials, Schizophrenia, Score

LB-102, Benzamide antipsychotic, Schizophrenia treatment, Phase II clinical trial, PANSS score reduction, First-in-class potential

Ring Therapeutics Undergoes Significant Restructuring, Laying Off Nearly Half of Its Workforce

4 months ago talkbio0Tagged Industry, restructuring, Ring (shape)

Ring Therapeutics, layoffs, workforce reduction, biotech industry, restructuring

Outlook Therapeutics Announces Strategic Workforce Reduction to Streamline Operations

4 months ago talkbio0Tagged AMD, Attitude, bevacizumab, biopharmaceutical company, cost-saving measures, Glycogen storage disease type II, Lytenava, restructuring, strategic

Outlook Therapeutics, workforce reduction, biopharmaceutical company, strategic restructuring, cost-saving measures, LYTENAVA, bevacizumab gamma, wet AMD treatment.